Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 434-280-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No toxicokinetic data are available on EC 434-280-4. Dissociation to the starting materials is expected to occur in aqueous media, and therefore, these are evaluated for any TK endpoints related to ingestion. EC 434-280-4 is expected to be stable as the final salt reaction product during use as a lubricant. As such, dermal exposure is likely to be to EC 434-280-4 as the salt and not the starting materials, at least for exposures of short duration. No Kow or water solubility data is available for EC 434-280-4 due to the rapid dissociation in water. However, a valid vapor pressure result for EC 434-280-4 demonstrates low inhalation exposure potential.
The physiochemical properties used in the TK assessment are in the table below (see attached document in Section 13 for Assessment approach that discusses the physiochemical properties and contains references).
Physical and Chemical Properties Relevant for the TK Assessment
Parameter | EC 434-280-4 | (Z)-octadec-9-enylamine (112-90-3) | Dibutyl hydrogen phosphate (CAS 107-66-4, AKA ‘DHP’) | Butyl dihydrogen phosphate (CAS 1623-15-0) | Di-n-hexyl dithiophosphoric acid (78-64-8, AKA DHDPA) |
Kow | NA | 7.5 (calculated) (EU RAR) | 0.57 (OECD, 1994) | -0.3 | 4.7 |
Water solubility | NA | Insoluble at 25 °C 0.07639 mg/L (calculated) (EU RAR) | 17 g/L (OECD, 1994) | 61 g/L | 1.2 mg/L |
Molecular weight | Variable | 267.5 | 210.2 | 154.1 | 298 |
Vapor pressure | 9.6E-6 Pa @ 25C | 0.005 hPa at 20 °C (EU RAR) | <7.4 x 10-3Pa at 100 °C (OECD, 1994) | <0.000015 Pa @ 20C | 3.79 x 10-5mmHg at 25°C* |
*EPI SUITE v. 4.1
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
Additional information
- Oral
Absorption
(Z)-octadec-9-enylamine (112-90-3)
The absorption of (Z)-octadec-9-enylamine was assessed by the EU in a Risk Assessment Report (2008). Based on the physical and chemical properties, the oral bioavailability is expected to be low. However, based on animal toxicology studies (acute and repeat dose), where effects were observed, absorption is known to occur through this route.
Dibutyl hydrogen phosphate (107-66-4)
Dibutyl hydrogen phospahte is likely bioavailable through the oral route. Based on the ECHA guidance R.7.C (R.7.12), the physical and chemical parameters are optimal for oral absorption:
- MW <500
- Highly water soluble
- Kow between -1 and 4
- Acute and repeat dose toxicity data indicate oral bioavailability (OECD, 1994)
Butyl dihydrogen phosphate (1623-15-0)
Butyl dihydrogen phosphate is likely bioavailable through the oral route. Based on the ECHA guidance R.7.C (R.7.12), the physical and chemical parameters are optimal for oral absorption:
- MW <500
- Highly water soluble
- Kow between -1 and 4
Di-n-hexyl dithiophosphoric acid (78-64-8)
Dihexyl dithiophosphate is expected to have limited oral bioavailability. Based on the ECHA guidance R.7.C (R.7.12), the physical and chemical parameters show some aspects that would favor oral absorption while other aspects are expected to limit oral bioavailability:
- Likely ionisable based on acid properties and the presence of a thiol group – this is expected to limit absorption
- MW <500
- Limited water solubility
- Kow greater than 4, which is not optimal for oral absorption
2. Dermal
(Z)-octadec-9-enylamine (112-90-3)
The TK of (Z)-octadec-9-enylamine was assessed by the EU in a Risk Assessment Report (2008). The dermal absorption is expected to be variable based on concentration (i.e., higher concentrations are corrosive, which will likely result in enhanced penetration through damaged skin) and physical state/presence of solvent. The EU RAR (2008) assumes 60% dermal absorption of primary alkyl amines as a worst-case scenario.
Dibutyl hydrogen phosphate (107-66-4)
Dibutyl hydrogen phosphate is likely bioavailable through the dermal route. Based on the ECHA guidance R.7.C (R.7.12), the physical and chemical parameters are optimal for dermal absorption:
- MW <500
- Water soluble
- Kow between -1 and 4
Butyl dihydrogen phosphate (1623-15-0)
Butyl dihydrogen phosphate is likely bioavailable through the dermal route. Based on the ECHA guidance R.7.C (R.7.12), the physical and chemical parameters are optimal for dermal absorption:
- MW <500
- Water soluble
- Kow between -1 and 4
Di-n-hexyl dithiophosphoric acid
Dihexyl dithiophosphate is expected to have limited dermal bioavailability. Based on the ECHA guidance R.7.C (R.7.12), the physical and chemical parameters show some aspects that would favor dermal absorption while other aspects are expected to limit dermal absorption:
- MW <500
- Limited water solubility – water solubility is expected to be approximately 1.2 mg/L and materials with water solubility less than 1 mg/L are expected to have low dermal bioavailability
- Kow greater than 4, which is not optimal for dermal absorption
3. Inhalation
EC 434-280-4 and the starting materials all have low vapor pressure, indicating that inhalation exposure is unlikely. Based on the physical and chemical properties, absorption through the respiratory tract if the material is aerosolized may occur. However, aerosolization is not expected to occur as a relevant exposure route.
Distribution
There are no to limited data on how the starting materials of EC 434-280-4 will distribute after absorption. (Z)-octadec-9-enylamine is the most relevant starting material as it is the source of the observed target organ toxicity. Based on the EU RAR (ECHA, 2008), primary alkyl amines are distributed into the lungs, brain, heart, spleen, kidney and liver. In addition, the repeat dose data for EC 434-280-4 (OECD 407) resulted in macrophage accumulation in the small intestine and mesenteric lymph nodes, most likely as a result of phagocytosed material.
Based on the Ps&Cs, DHP and BAP are likely distributed throughout the body.
Metabolism
For dibutyl hydrogen phosphate, butyl dihydrogen phosphate, and dihexyl dithiophosphate, metabolism is modeled using LMC OASIS TIMES v2.27.17.6 in vivo rat v.07.07 simulator to support literature information or where there is no existing metabolism information. All modeling reports are attached in separate TK endpoints.
(Z)-octadec-9-enylamine (112-90-3)
The metabolism of (Z)-octadec-9-enylamine was assessed by the EU in a Risk Assessment Report (2008). Alkylamines are oxidatively deaminated by monoaminooxidases forming ammonia and the corresponding alkylamine aldehyde. The aldehydes are then oxidised by aldehydedehydrogenases to the corresponding carboxylic acids, which are further metabolised by ß-oxidation.
Dibutyl hydrogen phosphate and butyl dihydrogen phosphate
A study with tributyl phosphate (CAS 126-73-8), administered a single I.P. dose to rats, found the principle metabolic pathway is a stepwise debutylation to yield predominantly dibutyl hydrogen phosphate and some butyl dihydrogen phosphate (Suzuki et al., 1984; OECD, 2001). This demonstrates that dibutyl phosphate will be metabolized to butyl dihydrogen phosphate, but the amount and rate is uncertain – based on the Suzuki et al (1984) study, only 11-21% was formed.
Dibutyl phosphate is metabolized by phosphate ester hydrolysis to the mono substituted alkyl phosphate (i.e., CAS 1623-15-0), which is demonstrated by modeling with OASIS TIMES in vivo rat metabolism simulator (v.07.11). Approximately 40% is predicted to undergo phosphate ester hydrolysis (modeling report attached; 40% is based on adding the mol/mol parent of all transformation products that have undergone phosphate ester hydrolysis). The substance has an observed map in the training set and is 100% in the models parametric and structural domain, demonstrating high confidence in this prediction.
For butyl dihydrogen phosphate, OASIS TIMES in vivo rat metabolism simulator (v.07.11) predicts glucuronidation will occur either directly to the free alcohol on the phosphate group or on the alkyl side chain after oxidation (approximately 75%). Approximately 25% will undergo dephosphorylation to butyl alcohol.
Di-n-hexyl dithiophosphoric acid (DHDPA)
OASIS TIMES in vivo rat metabolism simulator (v.07.11) predicts two primary routes of metabolism (approximately 50% each): The first is methylation of the sulfhydryl group; the second is oxidative desulfuration, transforming the thio group to an oxo group. After oxidative desulfuration, phosphate ester hydrolysis occurs followed by oxidation and glucuronidation.
Excretion
(Z)-octadec-9-enylamine (112-90-3)
According to the EU Risk Assessment Report (2008), (Z)-octadec-9-enylamine is excreted to a minor extent in the urine. Carbon dioxide, which is a final breakdown product formed, will be exhaled.
Dibutyl hydrogen phosphate and butyl dihydrogen phosphate
No information was found on the excretion. However, tributyl phosphate is primarily excreted via the urine (OECD, 2001). Therefore, it is likely that these two constituents of EC 434-280-4 are also excreted primarily through the urine.
Di-n-hexyl dithiophosphoric acid
No information is available on the route of excretion.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.